Morbid obesity is a significant health risk factor and its prevalence has increased in many industrialized countries in recent years. The principles of weight reduction have hardly changed over the years, but the range of approved drugs has expanded. Semaglutide and tirzepatide are the most commonly used today. Primary care providers play an important role in the individualized medical management of overweight patients.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Acute ischemic stroke
Alteplase and Tenecteplase Are on the Same Level
- CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment
SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes
- Wearables: screening via smartwatch?
New study on atrial fibrillation in high-risk patients
- Peristomal skin health
Focus on preventive care options
- Planning a Family, Pregnancy, and Breastfeeding
Update on Anti-Rheumatic Medications
- Mental Health with GLP-1 RAs
Benefits of Semaglutide and Liraglutide
- Bronchiolitis obliterans
Out of shape even without popcorn
- Case study